State Street SPDR S&P Biotech ETF (XBI) AIQ Analysis
State Street SPDR S&P Biotech ETF AIQ Score is 54/100 for investment merit, while Smart Score is 6/10 for peer-relative ranking, with Sharpe 1.99.
Last updated: Jul 26, 2026, 12:00 AM UTC
AIQ Brief
State Street SPDR S&P Biotech ETF is currently in a mixed setup with AIQ 54/100 and Smart 6/10 (neutral relative) at $150.48. Risk is moderate. Read this as a prioritization signal, then confirm entry quality and sizing with your own risk plan.
Quality is the strongest contributor at 61/100, while Momentum is the binding constraint at 43/100. With a 18-point spread, the profile is reasonably balanced without a single dominant weakness.
XBI ranks 3/4 in this peer set (54 vs peer average 53.8). On risk-adjusted efficiency, Sharpe is above peer average (1.99 vs 0.22). This helps distinguish true relative leadership from broad sector drift.
Action now: this is a neutral/selective setup. Improve entry quality by waiting for momentum acceleration or a better risk profile before adding. Keep sizing moderate until factors align.
Sharpe is 1.99, indicating strong risk-adjusted return for this snapshot.
| AIQ Component | Score | Signal Read |
|---|---|---|
| Momentum | 43 | Mixed trend quality with uneven follow-through. |
| Value | — | Value diagnostics are currently unavailable. |
| Quality | 61 | Quality profile is average for this universe. |
| Risk | 59 | Risk profile is moderate and manageable. |
| Sentiment | — | Sentiment signal is currently unavailable. |
Current AIQ Read
XBI currently screens as neutral. Wait for confirmation from trend quality and risk conditions before increasing exposure.
Loading XBI analysis...